The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Antibody Discovery

Antibody Discovery Services and Platforms Market (3rd Edition) by Service Offered (Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, Lead Characterization), by Antibody Discovery Method (Library based, Hybridoma based, Single Cell based, Transgenic Animal based), by Nature of Antibody Generated (Monoclonal, Bispecific, Antibody-Drug Conjugates, Antibody Fragments) and by Key Geographies: Industry Trends and Global Forecasts, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    July 2020

  • Pages
    460

  • View Count
    21544

  • Order Now

Example Insights

Antibody-Discovery-Services-and-Platforms-Market-Context Antibody-Discovery-Services-and-Platforms-Market-Service-Providers Antibody-Discovery-Services-and-Platforms-Market-Distribution Antibody-Discovery-Services-and-Platforms-Market-List-of-Antibody-Discovery-Platform-Providers
Antibody-Discovery-Services-and-Platforms-Market-Distribution-by-Antibody-Discovery-Method Antibody-Discovery-Services-and-Platforms-Market-Technology-Competitiveness-Analysis Antibody-Discovery-Services-and-Platforms-Market-Partnerships-and-Collaborations Antibody-Discovery-Services-and-Platforms-Market-Funding-and-Investments
Antibody-Discovery-Services-and-Platforms-Market-Opportunity-Analysis Antibody-Discovery-Services-and-Platforms-Market-Distribution-By-Geography    

 

 

Overview

With close to 80 monoclonal antibodies approved till date, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become an important part of the biopharmaceutical industry. In fact, they are presently estimated to constitute the largest class of biologics in the industry. Examples of recently approved monoclonal antibody products include (in reverse chronological order) Adakveo® (November 2019), Beovu® (October 2019), SKYRIZI™ (April 2019) and EVENITY™ (April 2019). These molecules have high target specificities and favorable safety profiles. Further, given the success of monoclonal antibodies, research on other novel antibody formats, such as bispecific antibodies, antibody drug conjugates (ADCs) and antibody fragments, has also gained traction. 

The development of such biologics is inherently complex, and many drug developers are now seeking to optimize R&D efficiency and affiliated costs. As a result, innovator companies are outsourcing most of their discovery-stage operations to specialty contract research organizations (CROs). Modern CROs are known to offer a plethora of advanced technologies to cater to the evolving needs. Apart from being considered a viable business strategy, engaging third party service providers offers both time and cost related benefits to drug / therapy developers. Therefore, as the demand for antibody based therapeutic / diagnostic products increases, the opportunity for contract service provides and technology developers is also anticipated to rise steadily in the foreseen future.

Scope of the Reports

The “Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution in this industry over the next ten years. The study underlines an in-depth analysis of the antibody discovery technologies and services that assist in the development of antibody therapeutics. In addition to other elements, it includes:

  • An overview of the overall landscape of antibody discovery service providers along with the information on a number of parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic). 
  • An insightful competitiveness analysis of antibody discovery service providers, based on supplier strength (based on a company’s employee count and years of experience) and service portfolio specifications, such as number of antibody discovery services offered, number of antibody discovery methods adopted, and number of subject specific agreements signed.
  • Elaborate profiles of antibody discovery service providers. Each company profile features a brief overview of the company, its financial information (if available), antibody discovery service portfolios and an informed future outlook. 
  • A detailed review of the overall landscape of antibody discovery platforms, along with the information on the technology developers such as year of establishment, company size, location of headquarters and type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others). In addition, the chapter highlights an in-depth analysis of antibody discovery platforms based on type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others) and availability of intellectual property.
  • A detailed competitiveness analysis of antibody discovery platforms, taking into consideration the supplier power (based on the year of establishment of developer) and key technology specifications, such as type of antibody discovered, compatibility of antibodies in human (fully human or not), availability of patent protection, number of deals signed for a particular platform between 2015 and 2020.  
  • Elaborate profiles of antibody discovery platform providers. Each company profile features a brief overview of the company, its financial information (if available), details on antibody discovery technology / platform(s) offered and an informed future outlook.
  • An assessment of antibody discovery service and platform providers’ capability in different regions, based on a number of relevant parameters. For platform providers, these parameters include number of technologies offered, number of antibody discovery methods employed, and type of antibody discovered. On the other hand, the service providers have been evaluated based on the type(s) of service offered.
  • An analysis of the partnerships that have been established in this domain since 2015, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, clinical trial agreements, and other relevant deals.
  • An analysis of the investments made in this domain, during the period between 2016 and 2020 (till April), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, in companies that are engaged in the field of antibody drug discovery. 
  • Detailed profiles on the top five therapeutic antibody products, which have generated the highest revenues. Each profile features a brief overview of the drug, the type of antibody discovery method it employs and the annual historical sales of the product.
  • A case study on antibody humanization and affinity maturation, including a list of players that are presently offering such services and platforms, a publication analysis highlighting the research trends in this field and a detailed discussion on other affiliated trends, key drivers and challenges, under a comprehensive SWOT framework.
  • A brief discussion on the imminent opportunities (such as novel antibody therapeutics, innovative technologies and other future opportunities) in the field of drug discovery that are likely to impact the future evolution of this market over the coming years.

One of the key objectives of the report was to estimate the existing market size and potential future opportunities for antibody discovery platforms and services, for the next decade. Based on parameters, such as the overall R&D expenditure available to CROs, percentage of R&D expenses incurred in each discovery step, and outsourcing profile, we have provided an informed estimate of the likely evolution of the antibody discovery services market in the mid to long term, for the time period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity within antibody discovery services market across [A] the various steps involved in antibody discovery process (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [B] antibody discovery methods (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), [C] the nature of antibody generated (whether human/ fully human or not) and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). In addition, for estimating the future market opportunities for platform providers, we have considered the likely licensing deal structures and agreements that are expected to be inked in the foreseen future. The future opportunities within the antibody discovery platforms market has been segmented across key geographical regions (North America, Europe and Asia- Pacific). The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Tracey Mullen (Chief Executive Officer, Abveris Antibody)
  • Lisa Delouise (Founder and Chief Technology Officer, Nidus Biosciences)
  • Mark Kubik (Chief Business Officer, AvantGen)
  • Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology)
  • Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio)
  • Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera)
  • Sanjiban K Banerjee (Director, AbGenics Life Sciences)
  • Ignacio Pino (Chief Executive Officer and President, CDI Laboratories) 
  • Jeng Her (Chief Executive Officer, AP Biosciences) 
  • Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB)
  • Debra Valsamis (Business Development Associate, Antibody Solutions)
  • Christel Iffland (Vice President, Ligand Pharmaceuticals)
  • Aaron Sato (former Chief Scientific Officer, LakePharma)

All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It presents a high-level view on the current scenario within the antibody discovery services and platform market and its evolution in the short-mid-term and long term.

Chapter 3 provides a general introduction of antibodies featuring details on their historical background, structure, isotypes, mechanism of action and applications. It also emphasizes on the different types of antibodies, namely monoclonal, bispecific and polyclonal antibodies.

Chapter 4 features a detailed overview on the antibody discovery process and the various methods used in the discovery of these therapeutic biomolecules. It also highlights a comparison of different antibody discovery methods that are currently available. Additionally, the chapter provides insights on the gradual shift in development trends of monoclonal antibodies over the last three decades, tracking the transition from fully murine to fully human product variants.

Chapter 5 provides a general overview of the current market landscape of more than 80 service providers that are currently active in this domain. It features a detailed analysis of these players based on several parameters, such as year of establishment, company size, location of headquarters, type of service offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), type of antibody discovery method (hybridoma based, library based, single cell based, transgenic animal based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others), type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others) and purpose of antibody discovery (therapeutic and diagnostic).

Chapter 6 provides an insightful competitiveness analysis of antibody discovery service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (based on the year of establishment of the service provider) and service strength (which takes into account the number of antibody discovery services offered, number of antibody discovery methods adopted, and number of subject specific agreements signed).

Chapter 7 provides detailed profiles of the stakeholders that are actively engaged in providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, its financial information (if available), details on antibody discovery services, recent developments and an informed future outlook.

Chapter 8 presents the current market landscape of over 120+ antibody discovery platform providers, including information on their company details such as year of establishment, company size, location of headquarters and type of antibody discovered (monoclonal antibody, bispecific antibody, single domain antibody, antibody drug conjugate, antibody fragment and others). In addition, the chapter highlights an in-depth analysis of 170+ antibody discovery platforms based on type of antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, and others), animal model used (rabbit, rat, mouse, llama, chicken, transgenic animal and others) and availability of intellectual property.

Chapter 9 provides an insightful competitiveness analysis of antibody discovery platforms. It highlights the leading players in this domain, taking into consideration the supplier power (based on the year of establishment of the platform provider) and key specifications of the platforms, such as types of antibody discovered, compatibility of antibodies in human (fully human or not), availability of patent protection, number of deals signed for a particular platform (2015-2020).  

Chapter 10 provides detailed profiles of the stakeholders, which actively provide access / licenses to their antibody discovery technology / platforms to other companies. Each company profile includes a brief overview of the company, its financial information (if available), details on antibody discovery technology / platforms, recent developments and an informed future outlook

Chapter 11 presents the antibody discovery capabilities in different regions, based on a number of relevant parameters, such as type of service offered for service providers, and number of technologies offered, number of antibody discovery methods and type of antibody discovered for platform providers.

Chapter 12 features an in-depth analysis and discussion on the various partnerships that have been inked between the players in this market in the time period between 2015 and 2020 (till March). It includes a brief description of partnership models (such as acquisitions, product development agreements, product integration agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements, and service agreements) adopted by the stakeholders.

Chapter 13 presents an analysis of the investments made in this domain during the period 2016-2020 (till April), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of discovery in companies that are focused on antibody discovery.

Chapter 14 features an insightful market forecast analysis, highlighting the likely growth of antibody discovery services domain till the year 2030. In order to provide details on the future opportunities, our projections have been segmented on the basis of  [A] the various steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [B] antibody discovery method (hybridoma based, library-based, single cell-based, transgenic animal-based, animal-based and others), [C] the nature of antibody generated (whether human/ fully human or not) and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). 

Chapter 15 presents the likely growth of antibody discovery platform market, on the basis of licensing deal structures and agreements signed or planned in the foreseen future. In order to provide details on the future opportunities, the projections have been segmented on the basis of 
key geographical regions (North America, Europe and Asia- Pacific).

Chapter 16 features detailed profiles of the most successful therapeutic monoclonal antibody products (as per sales reported in 2018). It provides information on top five drugs, namely Humira®, Keytruda®, Herceptin®, Avastin® and Rituxan®, their historical sales, and discovery process and methods.

Chapter 17 features a case study on antibody humanization and affinity maturation, highlighting the importance of these methods in the process of antibody discovery and development. The chapter presents a list of key players along with the information on their respective location, their expertise across antibody humanization and / or affinity maturation, the methodology adopted for providing such services and the revenue / business models adopted by the players involved in this domain. In addition, chapter provides insights on a publication analysis representing the recent trends in research on antibody humanization across various academic institutes, highlighting the ongoing innovation in this domain. Further, the report features a detailed SWOT analysis, which elaborates on the various drivers and challenges that are likely to influence the activities of players engaged in this domain.

Chapter 18 provides an overview of future growth opportunities in the field of antibody discovery. The chapter discusses the upcoming antibody therapeutics and technologies, which are being developed / adopted by the antibody drug discovery service and platform providers that are likely to have influence on the industry’s evolution over the coming decade.

Chapter 19 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (in alphabetical order of person name) Tracey Mullen (Chief Executive Officer, Abveris Antibody), Lisa Delouise (Founder and Chief Technology Officer, Nidus Biosciences), Mark Kubik (Chief Business Officer, AvantGen), Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology), Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio), Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera), Sanjiban K Banerjee (Director, AbGenics Life Sciences), Ignacio Pino (Chief Executive Officer and President, CDI Laboratories), Jeng Her (Chief Executive Officer, AP Biosciences), Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB), Debra Valsamis (Business Development Associate, Antibody Solutions),  Christel Iffland (Vice President, Ligand Pharmaceuticals), Aaron Sato (Chief Scientific Officer, LakePharma / Twist Biosciences)

Chapter 20 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it highlights the various evolutionary trends that are likely to determine the future of this segment of the antibody discovery service and platform market.

Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report.

Tables Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY

3. INTRODUCTION 
3.1. Chapter Overview
3.2. Structure of Antibodies
3.3. History of Development
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies 
3.6. Classification of Antibodies
3.6.1. Monoclonal Antibodies
3.6.2. Polyclonal Antibodies
3.6.3. Bispecific Antibodies
3.7. Applications of Antibodies

4. ANTIBODY DISCOVERY PROCESS AND METHODS
4.1. Chapter Overview
4.2. Antibody Discovery Process
4.2.1. Target Selection and Validation
4.2.2. Hit Generation
4.2.3. Lead Selection
4.2.4. Lead Optimization
4.2.4.1. Humanization
4.2.4.2. Affinity Maturation
4.2.4.3. Fc Engineering
4.2.5. Lead Characterization
4.2.6. Candidate Selection

4.3. Antibody Discovery Methods
4.3.1. Hybridoma Method
4.3.2. In vitro Display Method
4.3.2.1. Phage Display
4.3.2.2. Yeast Display
4.3.2.3. Ribosomal Display
4.3.3. Transgenic Animal-Based Method
4.3.4. Single B Cell-Based Method
4.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques

4.4. Evolution of Monoclonal Antibodies
4.4.1. Fully Human Monoclonal Antibodies

5. ANTIBODY DISCOVERY SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Antibody Discovery Service Providers: List of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Service Offered
5.2.5. Analysis by Type of Antibody Discovery Method
5.2.6. Grid Representation: Analysis by Type of Service Offered, Type of Antibody Discovery Method and Company Size
5.2.7. Analysis by Animal Model Used
5.2.8. Analysis by Type of Antibody Discovered
5.2.9. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered
5.2.10. Analysis by Purpose of Antibody Discovery
5.2.11. Analysis by Type of Antibody Discovery Method and Purpose of Antibody Discovery

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Key Parameters
6.4. Competitiveness Analysis: Antibody Discovery Service Providers
6.4.1. Antibody Discovery Service Providers based in North America
6.4.2. Antibody Discovery Service Providers based in Europe
6.4.3. Antibody Discovery Service Providers based in Asia Pacific

7. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers in North America
7.2.1. Abwiz Bio
7.2.1.1. Company Overview
7.2.1.2. Antibody Discovery Services
7.2.1.3. Recent Developments and Future Outlook

7.2.2. Aragen Bioscience (A GVK BIO Company)
7.2.2.1. Company Overview
7.2.2.2. Antibody Discovery Services
7.2.2.3. Recent Developments and Future Outlook

7.2.3. Distributed Bio
7.2.3.1. Company Overview
7.2.3.2. Antibody Discovery Services
7.2.3.3. Recent Developments and Future Outlook

7.2.4. Integral Molecular
7.2.4.1. Company Overview
7.2.4.2. Antibody Discovery Services
7.2.4.3. Recent Developments and Future Outlook

7.2.5. LakePharma
7.2.5.1. Company Overview
7.2.5.2. Antibody Discovery Services
7.2.5.3. Recent Developments and Future Outlook

7.3. Antibody Discovery Service Providers in Europe
7.3.1. Abzena
7.3.1.1. Company Overview
7.3.1.2. Financial Information
7.3.1.3. Antibody Discovery Services
7.3.1.4. Recent Developments and Future Outlook

7.3.2. ImmunoPrecise Antibodies
7.3.2.1. Company Overview
7.3.2.2. Financial Information
7.3.2.3. Antibody Discovery Services
7.3.2.4. Recent Developments and Future Outlook

7.3.3. PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group)
7.3.3.1. Company Overview
7.3.3.2. Antibody Discovery Services
7.3.3.3. Recent Developments and Future Outlook

7.4. Antibody Discovery Service Providers in Asia-Pacific
7.4.1. ChemPartner
7.4.1.1. Company Overview
7.4.1.2. Antibody Discovery Services
7.4.1.3. Recent Developments and Future Outlook

7.4.2. Viva Biotech
7.4.2.1. Company Overview
7.4.2.2. Financial Information
7.4.2.3. Antibody Discovery Services
7.4.2.4. Recent Developments and Future Outlook

7.4.3. WuXi Biologics
7.4.3.1. Company Overview
7.4.3.2. Financial Information
7.4.3.3. Antibody Discovery Services
7.4.3.4. Recent Developments and Future Outlook

8. ANTIBODY DISCOVERY TECHNOLOGIES: CURRENT MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Antibody Discovery Platform Providers: List of Industry Players
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size 
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Type of Antibody Discovered
8.3. Antibody Discovery: List of Technologies and Platforms
8.3.1. Analysis by Type of Antibody Discovery Method
8.3.2. Analysis by Type of Antibody Discovery Method and Location of Headquarters
8.3.3. Analysis by Animal Model Used
8.3.4. Analysis by Patent Availability

9. TECHNOLOGY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Methodology
9.3. Key Parameters
9.4. Technology Competitiveness Analysis: Antibody Discovery Platforms
9.4.1 Competitiveness Analysis: Library Based Antibody Discovery Platforms
9.4.2. Competitiveness Analysis: Single Cell Based Antibody Discovery Platforms
9.4.3. Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms
9.4.4. Competitiveness Analysis: Other Antibody Discovery Platforms

10. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
10.1. Chapter Overview
10.2. ImmunoPrecise Antibodies
10.2.1. Company Overview
10.2.2. Financial Information
10.2.3. Portfolio of Antibody Discovery Platforms
10.2.3.1. Abthena™
10.2.3.2. B cell Select™
10.2.3.3. DeepDisplay™
10.2.3.4. ModiFuse™
10.2.3.5. ModiPhage™
10.2.3.6. ModiSelect™
10.2.3.7. ModiTune™
10.2.4. Recent Developments and Future Outlook

10.3. Harbour BioMed
10.3.1. Company Overview
10.3.2. Portfolio of Antibody Discovery Platforms
10.3.2.1. H2L2 Platform
10.3.2.2. HCAb Platform
10.3.3. Recent Developments and Future Outlook 

10.4. Kymab
10.4.1. Company Overview
10.4.2. Portfolio of Antibody Discovery Platforms
10.4.2.1. Kymouse™
10.4.2.2. IntelliSelect®
10.4.3. Recent Developments and Future Outlook

10.5. Ligand Pharmaceuticals
10.5.1. Company Overview
10.5.2. Financial Information
10.5.3. Portfolio of Antibody Discovery Platforms
10.5.3.1. OmniAb®
10.5.3.1.1. OmniChicken®
10.5.3.1.2. OmniClic™
10.5.3.1.3. OmniFlic®
10.5.3.1.4. OmniMouse®
10.5.3.1.5. OmniRat®
10.5.4. Recent Developments and Future Outlook

10.6. MorphoSys
10.6.1. Company Overview
10.6.2. Financial Information
10.6.3. Portfolio of Antibody Discovery Platforms
10.6.3.1. arYla® Technology
10.6.3.2. HuCAL® Technology
10.6.3.3. Ylanthia® Technology
10.6.4. Recent Developments and Future Outlook

11. REGIONAL CAPABILITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Regional Capability Analysis: Antibody Discovery Service Providers
11.3.1 Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in North America
11.3.2. Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in Europe
11.3.3. Regional Capability Analysis: Distribution of Antibody Discovery Service Providers based in Asia-Pacific

11.4. Regional Capability Analysis: Antibody Discovery Platform Providers
11.4.1. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in North America
11.4.2. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in Europe
11.4.3. Regional Capability Analysis: Distribution of Antibody Discovery Platform Providers based in Asia-Pacific

11.5. Concluding Remarks

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by the Type of Company (Service / Platform Providers)
12.3.4. Analysis by Type of Antibody Discovered
12.3.5. Analysis by Year of Partnership and Type of Partner
12.3.6. Analysis by Type of Partnership and Type of Partner
12.3.7. Most Active Players: Analysis by Number of Partnerships
12.3.8. Most Popular Technologies: Analysis by Number of Partnerships
12.3.9. Regional Analysis
12.3.9.1. Intercontinental and Intracontinental Agreements

13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. Antibody Discovery Service and Platform Providers: Funding and Investment Analysis
13.3.1. Analysis by Number of Instances
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Most Active Players: Analysis by Amount Invested
13.3.5. Most Active Investors: Analysis by Number of Funding Instances
13.3.6. Regional Analysis by Amount Invested

13.4. Concluding Remarks

14. ANTIBODY DISCOVERY SERVICES: MARKET FORECAST
14.1. Chapter Overview
14.2. Forecast Methodology
14.3. Global Antibody Discovery Services Market, 2020-2030 
14.4. Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2020-2030
14.4.1. Antibody Discovery Services Market for Antigen Designing, 2020-2030
14.4.2. Antibody Discovery Services Market for Hit Generation, 2020-2030
14.4.3. Antibody Discovery Services Market for Lead Selection, 2020-2030
14.4.4. Antibody Discovery Services Market for Lead Optimization, 2020-2030
14.4.5. Antibody Discovery Services Market for Lead Characterization, 2020-2030
14.5. Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2020-2030
14.5.1. Antibody Discovery Services Market for Phage Display, 2020-2030
14.5.2. Antibody Discovery Services Market for Yeast Display, 2020-2030
14.5.3. Antibody Discovery Services Market for Hybridoma Method, 2020-2030
14.5.4. Antibody Discovery Services Market for Transgenic Animal Based Method, 2020-2030
14.5.5. Antibody Discovery Services Market for Single Cell Based Method, 2020-2030
14.5.6. Antibody Discovery Services Market for Other Methods, 2020-2030
14.6. Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2020-2030
14.6.1. Antibody Discovery Services Market for Humanized Antibodies, 2020-2030
14.6.2. Antibody Discovery Services Market for Human Antibodies, 2020-2030
14.6.3. Antibody Discovery Services Market for Chimeric Antibodies, 2020-2030
14.6.4. Antibody Discovery Services Market for Murine Antibodies, 2020-2030
14.7. Global Antibody Discovery Services Market: Distribution by Region, 2020-2030
14.7.1. Antibody Discovery Services Market in North America, 2020-2030
14.7.2. Antibody Discovery Services Market in Europe, 2020-2030 
14.7.3. Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2020-2030
14.7.4. Antibody Discovery Services: Market Attractiveness Analysis by Region

15. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET FORECAST
15.1. Chapter Overview
15.2. Key Assumptions
15.3. Forecast Methodology
15.4. Global Antibody Discovery Platforms Market, 2020-2030
15.5. Global Antibody Discovery Platforms Market: Distribution by Region, 2020-2030
15.5.1. Antibody Discovery Platforms Market in North America, 2020-2030
15.5.2. Antibody Discovery Platforms Market in Europe, 2020-2030
15.5.3. Antibody Discovery Platforms Market in Asia-Pacific, 2020-2030

16. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
16.1. Chapter Overview
16.2. Humira® (Adalimumab)
16.2.1. Drug Overview
16.2.2. Discovery Process and Method
16.2.3. Historical Sales

16.3. Keytruda® (Pembrolizumab)
16.3.1. Drug Overview
16.3.2. Discovery Process and Method
16.3.3. Historical Sales

16.4. Herceptin® (Trastuzumab)
16.4.1. Drug Overview
16.4.2. Discovery Process and Method
16.4.3. Historical Sales

16.5. Avastin® (Bevacizumab)
16.5.1. Drug Overview
16.5.2. Discovery Process and Method
16.5.3. Historical Sales

16.6. Rituxan® (Rituximab)
16.6.1. Drug Overview
16.6.2. Discovery Process and Method
16.6.3. Historical Sales

17. CASE STUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION
17.1. Importance of Antibody Humanization and Affinity Maturation
17.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: Market Landscape
17.3. Antibody Humanization: Publication Analysis
17.3.1. Publication Analysis: Year-Wise Trend
17.3.2. Publication Analysis: Key Journals
17.3.3. Publication Analysis: Distribution by Animal Model Used
17.3.4. Publication Analysis: Distribution by Method Used for Humanization
17.4. Antibody Humanization Service and Platform Providers: SWOT Analysis

18. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
18.1. Chapter Overview
18.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Formats
18.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
18.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
18.5. Rising Demand for Antibody-based Treatment Options across Non-Oncology Indications
18.6. Growing Market Opportunities in the Asia-Pacific Region
18.7. Expected Increase in Number of Collaborations and Licensing Activity
18.8 Concluding Remarks

19. EXECUTIVE INSIGHTS
19.1. Chapter Overview

19.2. Abveris Antibody
19.2.1. Company Snapshot
19.2.2. Tracey Mullen, Chief Executive Officer (Q2 2020)

19.3. Nidus Biosciences
19.3.1. Company Snapshot
19.3.2. Lisa Delouise, Founder and Chief Technology Officer (Q1 2020)

19.4. AvantGen
19.4.1. Company Snapshot
19.4.2. Mark Kubik, Chief Business Officer(Q1 2020)

19.5. Single Cell Technology
19.5.1. Company Snapshot
19.5.2. Chun-Nan Chen, Chief Executive Officer and Chief Scientific Officer (Q2 2018)

19.6. Distributed Bio
19.6.1. Company Snapshot
19.6.2. Giles Day, Co-Founder and Chief Executive Officer (Q2 2018)

19.7. AbCellera
19.7.1. Company Snapshot
19.7.2. Kevin Heyries, Co-Founder and Lead of Business Development Strategy (Q2 2018)

19.8. AbGenics Life Sciences
19.8.1. Company Snapshot
19.8.2. Sanjiban K Banerjee, Director (Q2 2018)

19.9. CDI Laboratories
19.9.1. Company Snapshot
19.9.2. Ignacio Pino, Chief Executive Officer and President (Q2 2017)

19.10. AP Biosciences
19.10.1. Company Snapshot
19.10.2. Jeng Her, Chief Executive Officer (Q2 2017)

19.11. YUMAB
19.11.1. Company Snapshot
19.11.2. Thomas Schirrmann, Chief Executive Officer and General Manager (Q2 2017)

19.12. Antibody Solutions
19.12.1. Company Snapshot
19.12.2. Debra Valsamis, Business Development Associate (Q2 2017)

19.13. Ligand Pharmaceuticals
19.13.1. Company Snapshot
19.13.2. Christel Iffland, Vice President (Q2 2017)

19.14. LakePharma
19.14.1. Company Snapshot
19.14.2. Aaron Sato, Chief Scientific Officer (Q2 2017)

20. CONCLUDING REMARKS
20.1. Chapter Overview
20.2. Key Takeaways

21. APPENDIX 1: TABULATED DATA

22. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 3.1 Basic Structure of an Antibody
Figure 3.2 Historical Timeline of Antibody Development
Figure 3.3 Mechanism of Action of Antibodies
Figure 3.4 Applications of Antibodies
Figure 4.1 Overview of the Antibody Discovery Process
Figure 4.2 Antibody Discovery Process: Hybridoma Method
Figure 4.3 Antibody Discovery Process: Phage Display Method
Figure 4.4 Antibody Generation Using Transgenic Animals
Figure 4.5 Approved Monoclonal Antibodies: Development Trend Analysis
Figure 4.6 Approval Timeline of Fully Human Monoclonal Antibody Therapeutics
Figure 4.7 Fully Human Monoclonal Antibodies: Distribution by Discovery Method
Figure 5.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Figure 5.2 Antibody Discovery Service Providers: Distribution by Company Size
Figure 5.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
Figure 5.4 World Map Representation: Analysis by Location by Headquarters
Figure 5.5 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Figure 5.6 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Figure 5.7 Grid Representation: Distribution by Type of Service Offered, Type of Antibody Discovery Method and Company Size
Figure 5.8 Antibody Discovery Service Providers: Distribution by Animal Model Used
Figure 5.9 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Figure 5.10 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method and Type of Antibody Discovered
Figure 5.11 Antibody Discovery Service Providers: Distribution by Purpose of Antibody Discovery
Figure 5.12 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method and Purpose of Antibody Discovery
Figure 6.1 Competitiveness Analysis: Antibody Discovery Service Providers based in North America
Figure 6.2 Competitiveness Analysis: Antibody Discovery Service Providers based in Europe
Figure 6.3 Competitiveness Analysis: Antibody Discovery Service Providers based in Asia-Pacific
Figure 7.1 Abzena: Annual Revenues, 2014-2018 (GBP Million)
Figure 7.2 ImmunoPrecise Antibodies: Annual Revenues, 2016-9M 2020 (USD Million)
Figure 7.3 Viva Biotech: Annual Revenues, 2016-2019 (RMB Million)
Figure 7.4 Wuxi Biologics: Annual Revenues, 2015-2019 (RMB Billion)
Figure 8.1 Antibody Discovery Platform Providers: Distribution by Year of Establishment
Figure 8.2 Antibody Discovery Platform Providers: Distribution by Company Size
Figure 8.3 Antibody Discovery Platform Providers: Distribution by Location of Headquarters
Figure 8.4 World Map Representation: Analysis by Location by Headquarters
Figure 8.5 Antibody Discovery Platform Providers: Distribution by Type of Antibody Discovered
Figure 8.6 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method
Figure 8.7 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method and Location of Headquarters
Figure 8.8 Antibody Discovery Platforms: Distribution by Animal Model Used
Figure 8.9 Antibody Discovery Platforms: Distribution by Patent Availability
Figure 9.1 Competitiveness Analysis: Library Based Antibody Discovery Platforms
Figure 9.2 Competitiveness Analysis: Single Cell Based Antibody Discovery Platforms
Figure 9.3 Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms
Figure 9.4 Competitiveness Analysis: Other Antibody Discovery Platforms
Figure 10.1 ImmunoPrecise Antibodies: Annual Revenues, 2016-9M 2020 (USD Million)
Figure 10.2 Ligand Pharmaceuticals: Annual Revenues, 2014-3M 2020 (USD Million)
Figure 10.3 MorphoSys: Annual Revenues, 2014-3M 2020 (USD Million)
Figure 11.1 Regional Capability Analysis: Antibody Discovery Service Providers based in North America
Figure 11.2 Regional Capability Analysis: Antibody Discovery Service Providers based in Europe
Figure 11.3 Regional Capability Analysis: Antibody Discovery Service Providers based in Asia-Pacific
Figure 11.4 Regional Capability Analysis: Concluding Remarks
Figure 12.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2020
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2020
Figure 12.4 Partnerships and Collaborations: Distribution by Type of Company (Service / Platform Providers)
Figure 12.5 Partnerships and Collaborations: Distribution by Type of Antibody Discovered
Figure 12.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 12.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 12.8 Most Active Players: Distribution by Number of Partnerships
Figure 12.9 Most Popular Technologies: Distribution by Number of Partnerships
Figure 12.10 Partnership and Collaborations: Regional Distribution
Figure 12.11 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 13.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2016-2020
Figure 13.2 Funding and Investment Analysis: Year-wise Distribution of Instances by Platform / Service Providers, (2016-2020)
Figure 13.3 Funding and Investment Analysis: Cumulative Amount Invested, 2016-2020 (USD Million)
Figure 13.4 Funding and Investment Analysis: Distribution by Instances Across the Amount Invested, 2016-2020 (USD Million)
Figure 13.5 Funding and Investment Analysis: Year-wise Distribution of the Amount Invested by Platform / Service Providers, 2016-2020 (USD Million)
Figure 13.6 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2016-2020
Figure 13.7 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2016-2020 (USD Million)
Figure 13.8 Funding and Investment Analysis: Summary of Investments, 2016-2020 (USD Million)
Figure 13.9 Funding and Investment Analysis: Most Active Players, 2016–2020 (USD Million)
Figure 13.10 Funding and Investment Analysis: Most Active Investors
Figure 13.11 Funding and Investment Analysis: Distribution by Geography
Figure 13.12 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 13.13 Funding and Investment Summary, 2016-2020 (USD Million)
Figure 14.1 Global Antibody Discovery Services Market, 2020-2030 (USD Billion)
Figure 14.2 Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2020-2030
Figure 14.3 Antibody Discovery Services Market for Antigen Designing, 2020-2030
Figure 14.4 Antibody Discovery Services Market for Hit Generation, 2020-2030
Figure 14.5 Antibody Discovery Services Market for Lead Selection, 2020-2030
Figure 14.6 Antibody Discovery Services Market for Lead Optimization, 2020-2030
Figure 14.7 Antibody Discovery Services Market for Lead Characterization, 2020-2030
Figure 14.8 Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2020-2030
Figure 14.9 Antibody Discovery Services Market for Phage Display, 2020-2030
Figure 14.10 Antibody Discovery Services Market for Yeast Display, 2020-2030
Figure 14.11 Antibody Discovery Services Market for Hybridoma Method, 2020-2030
Figure 14.12 Antibody Discovery Services Market for Transgenic Animal Based Method, 2020-2030
Figure 14.13 Antibody Discovery Services Market for Single Cell Based Method, 2020-2030
Figure 14.14 Antibody Discovery Services Market for Other Methods, 2020-2030
Figure 14.15 Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2020-2030
Figure 14.16 Antibody Discovery Services Market for Humanized Antibodies, 2020-2030
Figure 14.17 Antibody Discovery Services Market for Human Antibodies, 2020-2030
Figure 14.18 Antibody Discovery Services Market for Chimeric Antibodies, 2020-2030
Figure 14.19 Antibody Discovery Services Market for Murine Antibodies, 2020-2030
Figure 14.20 Global Antibody Discovery Services Market: Distribution by Region, 2020-2030
Figure 14.21 Antibody Discovery Services Market in North America, 2020-2030
Figure 14.22 Antibody Discovery Services Market in Europe, 2020-2030
Figure 14.23 Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2020-2030
Figure 14.24 Antibody Discovery Services: Market Attractiveness Analysis by Region
Figure 15.1 Licensing Agreements: Distribution of Financial Components
Figure 15.2 Technology Licensing Deal: Payment Structure
Figure 15.3 Global Antibody Discovery Platforms Market, 2020-2030 (USD Million)
Figure 15.4 Global Antibody Discovery Platforms Market: Distribution by Region, 2020-2030 (USD Million)
Figure 15.5 Antibody Discovery Platforms Market in North America, 2020-2030
Figure 15.6 Antibody Discovery Platforms Market in Europe, 2020-2030
Figure 15.7 Antibody Discovery Platforms Market in Asia-Pacific, 2020-2030
Figure 16.1 Humira®: Annual Sales, 2013-2019 (USD Billion)
Figure 16.2 Keytruda®: Annual Sales, 2014-2019 (USD Billion)
Figure 16.3 Herceptin®: Annual Sales, 2013-2019 (USD Billion)
Figure 16.4 Avastin®: Annual Sales, 2013-2019 (USD Billion)
Figure 16.5 Rituxan®: Annual Sales, 2013-2019 (USD Billion)
Figure 17.1 Publication Analysis: Quarterly Distribution
Figure 17.2 Publication Analysis: Distribution by Key Journals
Figure 17.3 Publication Analysis: Distribution by Study Model
Figure 17.4 Publication Analysis: Distribution by Method Used for Humanization
Figure 17.6 Antibody Humanization Service and Platform Providers: SWOT Analysis
Figure 17.7 Antibody Humanization Service and Platform Providers: Strengths Overview
Figure 17.8 Antibody Humanization Service and Platform Providers: Weaknesses Overview
Figure 17.9 Antibody Humanization Service and Platform Providers: Opportunities Overview
Figure 17.10 Antibody Humanization Service and Platform Providers: Threats Overview
Figure 18.1 Future Opportunities Related to Upcoming Trends in Drug Discovery
Figure 18.2 Number of Licensing Deals, 2015- 2020

List Of Tables

Table 3.1 Antibody Isotypes: Key Features
Table 3.2 Mechanism of Action of Therapeutic Antibodies against Different Target Classes
Table 3.3 Differences Between Polyclonal and Monoclonal Antibodies
Table 4.1 Antibody Discovery Methods: Advantages and Disadvantages
Table 4.2 List of Approved Monoclonal Antibodies
Table 5.1 List of Antibody Discovery Service Providers
Table 5.2 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Table 5.3 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Table 5.4 Antibody Discovery Service Providers: Distribution by Animal Model Used
Table 5.5 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Table 5.6 Antibody Discovery Service Providers: Distribution by Purpose of Antibody Discovery
Table 7.1 Antibody Discovery Service Providers: List of Companies Profiled
Table 7.2 Abwiz Bio: Recent Developments and Future Outlook
Table 7.3 Aragen Bioscience: Recent Developments and Future Outlook
Table 7.4 Distributed Bio: Recent Developments and Future Outlook
Table 7.5 Integral Molecular: Recent Developments and Future Outlook
Table 7.6 LakePharma: Recent Developments and Future Outlook
Table 7.7 Abzena: Recent Developments and Future Outlook
Table 7.8 ImmunoPrecise Antibodies: Recent Developments and Future Outlook
Table 7.9 PX'Therapeutics (Subsidiary of Aguettant Pharmaceutical Group): Recent Developments and Future Outlook
Table 7.10 ChemPartner: Recent Developments and Future Outlook
Table 7.11 Viva Biotech: Recent Developments and Future Outlook
Table 7.12 Wuxi Biologics: Recent Developments and Future Outlook
Table 8.1 List of Antibody Discovery Platform Providers
Table 8.2 Antibody Discovery Platform Providers: Distribution by Type of Antibody Discovered
Table 8.3 Antibody Discovery: List of Technologies and Platforms
Table 8.4 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method
Table 8.5 Antibody Discovery Platforms: Distribution by Animal Model Used
Table 8.6 Antibody Discovery Platforms: Distribution by Patent Availability
Table 10.1 Antibody Discovery Platform Providers: List of Companies Profiled
Table 10.2 ImmunoPrecise Antibodies: Recent Developments and Future Outlook
Table 10.3 Harbour BioMed: Recent Developments and Future Outlook
Table 10.4 Kymab: Recent Developments and Future Outlook
Table 10.5 OmniAb® Technology: Patent Information
Table 10.6 OmniChicken® Technology: Patent Information
Table 10.7 Ligand Pharmaceuticals: Recent Developments and Future Outlook
Table 10.8 MorphoSys: Recent Developments and Future Outlook
Table 11.1 Regional Capability Analysis: Antibody Discovery Platform Providers based in North America
Table 11.2 Regional Capability Analysis: Antibody Discovery Platform Providers based in Europe
Table 11.3 Regional Capability Analysis: Antibody Discovery Platform Providers based in Asia-Pacific
Table 12.1 Antibody Discovery Service and Platform Providers: Partnerships and Collaboration, 2015-2020
Table 13.1 Antibody Discovery Service and Platform Providers: Funding and Investment, 2016-2020
Table13.2 Funding and Investment Analysis: Summary of Investments
Table 15.1 Developmental / Regulatory Milestones
Table 15.2 Antibody Discovery Platforms: Average Upfront and Average Milestone Payments (USD Million)
Table 16.1 Top Ten Selling Therapeutic Antibodies, 2018
Table 17.1 Approved Monoclonal Antibodies: Information on Affinity
Table 17.2 Antibody Humanization and Affinity Maturation: Service and Platform Providers
Table 17.3 Antibody Humanization and Affinity Maturation: Description of Services and Platform Providers
Table 17.4 Antibody Humanization: Recent Publications
Table 17.5 Antibody Humanization: Modified CDR Grafting Methods
Table 18.1 Antibody Discovery Services and Platform Providers: Asia-Pacific Region
Table 19.1 Company Snapshot: Abveris Antibody
Table 19.2 Company Snapshot: Nidus Biosciences
Table 19.3 Company Snapshot: AvantGen
Table 19.4 Company Snapshot: Single Cell Technology
Table 19.5 Company Snapshot: Distributed Bio
Table 19.6 Company Snapshot: AbCellera
Table 19.7 Company Snapshot: AbGenics Life Sciences
Table 19.8 Company Snapshot: CDI Laboratories
Table 19.9 Company Snapshot: AP Biosciences
Table 19.10 Company Snapshot: YUMAB
Table 19.12 Company Snapshot: Antibody Solutions
Table 19.13 Company Snapshot: Ligand Pharmaceuticals
Table 19.14 Company Snapshot: LakePharma
Table 21.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Table 21.2 Antibody Discovery Service Providers: Distribution by Company Size
Table 21.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters
Table 21.4 Antibody Discovery Service Providers: Distribution by Type of Service Offered
Table 21.5 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Table 21.6 Antibody Discovery Service Providers: Distribution by Animal Model Used
Table 21.7 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Table 21.8 Antibody Discovery Service Providers: Distribution by Purpose of Antibody Discovery
Table 21.9 Abzena: Annual Revenues, 2014-2018 (GBP Million)
Table 21.10 ImmunoPrecise Antibodies: Annual Revenues, 2016-9M 2020 (USD Million)
Table 21.11 Viva Biotech: Annual Revenues, 2016-2019 (RMB Million)
Table 21.12 Wuxi Biologics: Annual Revenues, 2015-2019 (RMB Billion)
Table 21.13 Antibody Discovery Platform Providers: Distribution by Year of Establishment
Table 21.14 Antibody Discovery Platform Providers: Distribution by Company Size
Table 21.15 Antibody Discovery Platform Providers: Distribution by Location of Headquarters
Table 21.16 Antibody Discovery Platform Providers: Distribution by Type of Antibody Discovered
Table 21.17 Antibody Discovery Platforms: Distribution by Type of Antibody Discovery Method
Table 21.18 Antibody Discovery Platforms: Distribution by Animal Model Used
Table 21.19 Antibody Discovery Platforms: Distribution by Patent Availability
Table 21.20 ImmunoPrecise Antibodies: Annual Revenues, 2016-9M 2020 (USD Million)
Table 21.21 Ligand Pharmaceuticals: Annual Revenues, 2014-3M 2020 (USD Million)
Table 21.22 MorphoSys: Annual Revenues, 2014-3M 2020 (USD Million)
Table 21.23 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2020
Table 21.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 21.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2020
Table 21.26 Partnerships and Collaborations: Distribution by Type of Company (Service / Platform Providers)
Table 21.27 Partnerships and Collaborations: Distribution by Type of Antibody Discovered
Table 21.28 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 21.29 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 21.30 Most Active Players: Distribution by Number of Partnerships
Table 21.31 Most Popular Technologies: Distribution by Number of Partnerships
Table 21.32 Partnership and Collaborations: Regional Distribution
Table 21.33 Funding and Investment Analysis: Cumulative Year-wise Trend, 2016-2020
Table 21.34 Funding and Investment Analysis: Year-wise Distribution of Instances by Platform / Service Providers, (2016-2020)
Table 21.35 Funding and Investment Analysis: Cumulative Amount Invested, 2016-2020 (USD Million)
Table 21.36 Funding and Investment Analysis: Distribution by Instances across the Amount Invested, 2016-2020 (USD Million)
Table 21.37 Funding and Investment Analysis: Year-wise Distribution of the Amount Invested by Platform / Service Providers, 2016-2020 (USD Million)
Table 21.38 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2016-2020
Table 21.39 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2016-2020 (USD Million)
Table 21.40 Funding and Investment Analysis: Most Active Players, 2016–2020 (USD Million)
Table 21.41 Funding and Investment Analysis: Most Active Investors
Table 21.42 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 21.43 Global Antibody Discovery Services Market, 2020-2030 (USD Billion): Base, Conservative and Optimistic Scenarios
Table 21.44 Global Antibody Discovery Services Market: Distribution by Steps Involved in Antibody Discovery Process, 2020-2030: Base, Conservative and Optimistic Scenarios
Table 21.45 Antibody Discovery Services Market for Antigen Designing, 2020-2030
Table 21.46 Antibody Discovery Services Market for Hit Generation, 2020-2030
Table 21.47 Antibody Discovery Services Market for Lead Selection, 2020-2030
Table 21.48 Antibody Discovery Services Market for Lead Optimization, 2020-2030
Table 21.49 Antibody Discovery Services Market for Lead Characterization, 2020-2030
Table 21.50 Global Antibody Discovery Services Market: Distribution by Antibody Discovery Method, 2020-2030: Base, Conservative and Optimistic Scenarios
Table 21.51 Antibody Discovery Services Market for Phage Display, 2020-2030
Table 21.52 Antibody Discovery Services Market for Yeast Display, 2020-2030
Table 21.53 Antibody Discovery Services Market for Hybridoma Method, 2020-2030
Table 21.54 Antibody Discovery Services Market for Transgenic Animal Based Method, 2020-2030
Table 21.55 Antibody Discovery Services Market for Single Cell Based Method, 2020-2030
Table 21.56 Antibody Discovery Services Market for Other Methods, 2020-2030
Table 21.57 Global Antibody Discovery Services Market: Distribution by Nature of Antibody Generated, 2020-2030: Base, Conservative and Optimistic Scenarios
Table 21.58 Antibody Discovery Services Market for Humanized Antibodies, 2020-2030
Table 21.59 Antibody Discovery Services Market for Human Antibodies, 2020-2030
Table 21.60 Antibody Discovery Services Market for Chimeric Antibodies, 2020-2030
Table 21.61 Antibody Discovery Services Market for Murine Antibodies, 2020-2030
Table 21.62 Global Antibody Discovery Services Market: Distribution by Region, 2020-2030: Base, Conservative and Optimistic Scenarios
Table 21.63 Antibody Discovery Services Market in North America, 2020-2030
Table 21.64 Antibody Discovery Services Market in Europe, 2020-2030
Table 21.65 Antibody Discovery Services Market in Asia-Pacific and Rest of the World, 2020-2030
Table 21.66 Global Antibody Discovery Platforms Market, 2020-2030 (USD Million): Base, Conservative and Optimistic Scenarios
Table 21.67 Global Antibody Discovery Platforms Market: Distribution by Region, 2020-2030 (USD Million): Base, Conservative and Optimistic Scenarios
Table 21.68 Antibody Discovery Platforms Market in North America, 2020-2030
Table 21.69 Antibody Discovery Platforms Market in Europe, 2020-2030
Table 21.70 Antibody Discovery Platforms Market in Asia-Pacific, 2020-2030
Table 21.71 Humira®: Annual Sales, 2013-2019 (USD Billion)
Table 21.72 Keytruda®: Annual Sales, 2014-2019 (USD Billion)
Table 21.73 Herceptin®: Annual Sales, 2013-2019 (USD Billion)
Table 21.74 Avastin®: Annual Sales, 2013-2019 (USD Billion)
Table 21.75 Rituxan®: Annual Sales, 2013-2019 (USD Billion)
Table 21.76 Number of Licensing Deals, 2015- 2020

List of Companies

The following companies and organizations have been mentioned in the report:

  1. 3E Bioventures Capital
  2. 3SBio
  3. A*STAR's Genome Institute of Singapore
  4. Ab Initio Biotherapeutics
  5. Ab Studio
  6. ABBA Therapeutics
  7. AbBioSci
  8. AbbVie
  9. Abcam
  10. AbCellera
  11. Abcentra
  12. AbCheck
  13. Abeome
  14. AbGenics Life Sciences
  15. ABL Bio
  16. Ablexis
  17. Abpro
  18. Absolute Antibody
  19. AbVision
  20. Abwiz Bio
  21. Abzena
  22. Abzyme Therapeutics
  23. AC Immune
  24. Accel
  25. Acceleron Pharma
  26. Accurus Biosciences
  27. Achaogen
  28. ACYTE Biotech
  29. Adagene
  30. Adaptate Biotherapeutics
  31. Adimab
  32. Aduro Biotech
  33. Advantech
  34. Advantech Capital
  35. AffinityImmuno
  36. Affitech
  37. Agency for Science, Technology and Research
  38. Agenus
  39. AIMM Therapeutics
  40. Aimmune Therapeutics
  41. Aisling Capital
  42. Akeagen 
  43. Akeso Biopharma
  44. Aldevron
  45. Alector
  46. Alligator Bioscience
  47. Allogene Therapeutics
  48. Alloy Therapeutics
  49. Ally Bridge Group
  50. Alta Partners
  51. Alzheimer's Drug Discovery Foundation
  52. Amgen
  53. Amgen Ventures
  54. Ampersand Capital Partners
  55. AnaImmune
  56. Analytics Engine
  57. AnaptysBio
  58. Andera Partners
  59. Antagene
  60. Antibody Design Labs
  61. Antibody Solutions
  62. Antiverse
  63. AP Biosciences
  64. Apexigen
  65. Aptevo Therapeutics
  66. Aquila BioMedical
  67. Aquila Capital
  68. Aquilo Capital Management
  69. Aragen Bioscience
  70. ARCH Venture Partners
  71. Arcus Biosciences
  72. argenx
  73. Aridis Pharmaceuticals
  74. Aro Biotherapeutics
  75. Aronora
  76. Arsanis
  77. Artizan Biosciences
  78. Assistant Secretary for Preparedness and Response
  79. Astellas Pharma
  80. AstraZeneca
  81. aTen Therapeutics
  82. Atreca
  83. Autolus Therapeutics
  84. AvantGen
  85. AVIC Capital
  86. AxioMx
  87. Ballast Point Ventures
  88. Bayer
  89. BBI Group
  90. BeiGene
  91. Beijing Shijilongxin Investment
  92. Berkeley Lights
  93. Betta Pharmaceuticals
  94. Bhami’s Research Laboratory
  95. Bharat Innovation Fund
  96. Bill & Melinda Gates Foundation
  97. BioAtla
  98. Biocytogen
  99. BioDiscovery
  100. BioDuro
  101. Biogen
  102. BioInvent
  103. Biomatics Capital
  104. BioNTech
  105. Bio-Rad Laboratories
  106. BioSavita
  107. Biosion
  108. Biotechnology Value Fund
  109. Biotecnol
  110. BIOTEM
  111. Biotheus
  112. Birchmere Labs
  113. Bird Rock Bio
  114. Blue Sky BioServices
  115. bluebird bio
  116. Boehringer Ingelheim
  117. Boston Children's Hospital
  118. Boxer Capital
  119. Brain Canada
  120. Bristol-Myers Squibb
  121. Broteio Pharma
  122. Burrage Capital
  123. CALIXAR
  124. CANbridge
  125. Cancer Prevention and Research Institute of Texas
  126. Carterra
  127. Catalent Biologics
  128. CBC Group
  129. CCB Capital
  130. CDH Investments
  131. CDI Laboratories
  132. Celexion
  133. Celgene
  134. Cell Signaling Technology
  135. Celsius Therapeutics
  136. Centers for Disease Control and Prevention (CDC)
  137. Charles River Laboratories
  138. ChemBio Discovery Solutions
  139. Chemical Abstracts Service (CAS)
  140. ChemPartner
  141. Chia Tai Tianqing Pharmaceutical 
  142. China Life Investment Holding
  143. China Life Private Equity Investment
  144. ChinaEquity Group (CEG)
  145. Chiome Bioscience
  146. Chugai Pharmabody Research
  147. Chugai Pharmaceutical
  148. Cilag
  149. Citryll
  150. City of Hope
  151. Columbia University Irving Medical Center
  152. Compass Therapeutics
  153. Cormorant Asset Management
  154. Corvidia Therapeutics
  155. Cosmo Bio
  156. Cowen Healthcare Investments
  157. Cowin Venture Capital
  158. CR-CP Life Science Fund
  159. Creative Biolabs
  160. Creative Biostructure
  161. Creative Diagnostics
  162. Crescendo Biologics
  163. Crystal Bioscience
  164. CSL Behring
  165. CStone Pharmaceuticals
  166. CureVac
  167. CUSABIO TECHNOLOGY
  168. DAFNA Capital Management
  169. Daiichi Sankyo
  170. Dako
  171. Dana-Farber Cancer Institute
  172. DCVC (Data Collective) 
  173. DaTaMabs
  174. Decheng Capital
  175. Defense Advanced Research Projects Agency (DARPA)
  176. Delian Capital
  177. Denali Therapeutics
  178. Dianomi Therapeutics
  179. Diatheva
  180. Digital Proteomics
  181. Distributed Bio
  182. DJS Antibodies
  183. Early Drug Development Group (E2DG)
  184. EcoR1 Capital
  185. Efung Capital
  186. Eight Roads
  187. Eisai
  188. Eli Lilly and Company
  189. Elpis Biopharmaceuticals
  190. Emergent BioSolutions
  191. Enterprise Singapore
  192. Enthera
  193. Entos Pharmaceuticals
  194. EpimAb Biotherapeutics
  195. Epiphron Capital Group
  196. Eureka Therapeutics
  197. European Investment Bank
  198. European Molecular Biology Laboratory (EMBL)
  199. Eurostars
  200. Evotec
  201. Exelixis
  202. Exiris
  203. exonbio
  204. FairJourney Biologics
  205. Faron Pharmaceuticals
  206. FCMI Parent
  207. Ferring Pharmaceuticals
  208. Five Prime Therapeutics
  209. Flagship Pioneering
  210. Flanders Innovation and Entrepreneurship
  211. Floodgate
  212. ForteBio
  213. Fortune Capital Services
  214. Forty Seven
  215. F-Prime Capital
  216. Fred Hutchinson Cancer Research Center
  217. FREJOY Investment Management
  218. Fusion Antibodies
  219. Fusion Pharmaceuticals
  220. G&P Biosciences
  221. G.N. Tech Venture
  222. Genagon Therapeutics
  223. Genedata Biologics
  224. GeneFrontier
  225. Geneious Biologics
  226. General Atlantic
  227. Genmab
  228. Genor Biopharma
  229. GenScript
  230. GHO Capital
  231. GIC
  232. GigaGen
  233. Gilead Sciences
  234. Glenmark Pharmaceuticals
  235. Glythera
  236. Gopher Asset Management
  237. GP Healthcare Capital
  238. Grenoble Alpes University Hospital
  239. Grifols
  240. GlaxoSmithKline
  241. Gustave Roussy
  242. GV20 Oncotherapy
  243. H3 Biomedicine
  244. Harbour BioMed
  245. Harpoon Therapeutics
  246. HD Biosciences
  247. Henlix Biotech
  248. Heptares Therapeutics
  249. Hercules Capital
  250. Heritas Capital Management
  251. HiFiBiO Therapeutics
  252. Hillhouse Capital Group
  253. HJB
  254. Hony Capital
  255. HOPU Investments
  256. Huaxing Growth Capital
  257. Hummingbird Bioscience
  258. i2 Pharmaceuticals
  259. Ibex Biosciences
  260. Icosagen
  261. IDG Capital
  262. IFB Hamburg
  263. IGEM Therapeutics
  264. I-Mab Biopharma
  265. iMetabolic Biopharma
  266. Immatics Biotechnologies
  267. Immune Biosolutions
  268. Immune Pharmaceuticals
  269. ImmunoChina Pharmaceuticals
  270. ImmunoGenes
  271. Immunome
  272. Immunomic Therapeutics
  273. ImmunoPrecise Antibodies
  274. ImmunoQure
  275. In-Cell-Art
  276. Incyte
  277. Indivumed
  278. Inhibrx
  279. Innate Pharma
  280. Innogene Kalbiotech
  281. Innovate UK
  282. Innovative Targeting Solutions
  283. Innovent Biologics
  284. Institut National de la Santé et de la Recherche Médicale (INSERM)
  285. Institute for Research in Biomedicine
  286. Intarcia Therapeutics
  287. IntelliCyt
  288. Integral Molecular
  289. Invenra
  290. Invest Northern Ireland
  291. IONTAS
  292. IP Group 
  293. Isogenica
  294. Italian National Institute of Health
  295. ITBMed
  296. iTeos Therapeutics
  297. Janssen Biotech
  298. JDRF T1D Fund
  299. Jiangsu Hengrui Medicine
  300. Johnson & Johnson Innovation
  301. Jounce Therapeutics
  302. Juno Therapeutics
  303. Just Biotherapeutics (Acquired by Evotec)
  304. Kadmon
  305. Kaken Pharmaceutical
  306. Keystone Capital Partners
  307. Kite Pharma
  308. Kodiak Sciences
  309. Kymab
  310. LakePharma
  311. LAMPIRE Biological Laboratories
  312. Lava Therapeutics
  313. Leading Biology
  314. Legend Capital
  315. Legend Star
  316. Leidos Biomedical Research
  317. LEO Pharma
  318. LG Chem
  319. Life Science Partners
  320. LifeArc
  321. Ligand Pharmaceuticals
  322. Light Chain Bioscience
  323. Lilly Ventures
  324. Lineage Biosciences (Acquired by AbCellera)
  325. Linear Venture
  326. Lipum
  327. Lonza
  328. Lundbeck
  329. LYFE Capital
  330. MAB Discovery
  331. Mablytics
  332. Mabpharm
  333. MabSpace Biosciences
  334. MabVax Therapeutics
  335. MacroGenics
  336. Magenta Therapeutics
  337. Maine Biotechnology Services
  338. Malin
  339. Massachusetts General Hospital
  340. MassBiologics
  341. Maverick Therapeutics
  342. MD Anderson Cancer Center
  343. MedAbome
  344. MedImmune
  345. MEMO Therapeutics
  346. Memorial Sloan Kettering Cancer Center
  347. Merck
  348. Merus
  349. MI-mAbs 
  350. Mirae Asset Financial Group
  351. Mitsubishi Tanabe Pharma
  352. Mitsubishi UFJ Capital
  353. ModiQuest Research
  354. Molcure
  355. Molecular Devices
  356. Molecular Templates
  357. MolMed
  358. Moradec
  359. MorphoSys
  360. Mount Sinai Health System
  361. MPM Capital
  362. MRL Ventures Fund
  363. MSM Protein Technologies
  364. Mycenax Biotech
  365. National Cancer Institute
  366. National Centre for Biomolecular Research
  367. National Center for Research and Development
  368. National Heart, Lung and Blood Institute
  369. National Institute of Allergy and Infectious Diseases
  370. National Institutes of Health
  371. National Institute of General Medical Sciences
  372. NanoString Technologies
  373. NB Health Laboratory
  374. NBE-Therapeutics
  375. NeoBiotechnologies
  376. NeoClone
  377. Neon Therapeutics
  378. neoX Biotech
  379. Nest.Bio Ventures
  380. Neurimmune
  381. New World TMT
  382. Nidus BioSciences
  383. NJCTTQ
  384. Nkarta Therapeutics
  385. North Coast Biologics
  386. NovaRock Biotherapeutics
  387. Novartis
  388. Novo Nordisk
  389. Numab Therapeutics
  390. NYU Langone Health
  391. Oceanpine Capital
  392. Olympic Protein Technologies
  393. Oncothyreon
  394. Ono Pharmaceutical
  395. Open Monoclonal Technology
  396. OrbiMed Advisors
  397. OREGA Biotech
  398. ORI Healthcare Fund
  399. OriGene Technologies
  400. OriMAbs
  401. Ossianix
  402. Oxford Sciences Innovation
  403. Paladin Capital Group
  404. Pandion Therapeutics 
  405. Panoply Bio
  406. Pediatric Brain Tumor Consortium
  407. Penn Medicine
  408. Pennsylvania Industrial Development Authority
  409. Pfizer
  410. pH Pharma
  411. Phanes Therapeutics
  412. PharmAbcine
  413. PharmaLegacy
  414. Pierre Fabre
  415. Polaris Partners
  416. Potenza Therapeutics
  417. PPF Group
  418. Precision Antibody
  419. Protein Alternatives (PROALT)
  420. ProteoGenix
  421. ProtTech
  422. Proxima Ventures
  423. Purdue Pharma
  424. Pure Biologics
  425. PX'Therapeutics
  426. Qianhai Qinzhi Capital
  427. Qiming Venture Partners
  428. QIMR Berghofer Medical Research Institute
  429. QoolAbs
  430. Quan Funds
  431. Quebec Consortium for Drug Discovery (CQDM)
  432. Queen's University
  433. Redalpine Venture Partners
  434. Redmile Group
  435. Regeneron Pharmaceuticals
  436. Regione Lazio
  437. Resonant Therapeutics
  438. Retrogenix
  439. Revolve Biotechnologies
  440. Rezolute
  441. Rhenman & Partners Asset Management
  442. Roche
  443. RubrYc Therapeutics
  444. Rx Biosciences
  445. SAB Biotherapeutics
  446. Samsara BioCapital
  447. Samsara Networks
  448. San Diego Biomedical Research Institute
  449. Sanofi
  450. Sanyou Biopharmaceuticals
  451. SARomics Biostructures
  452. Schroder Adveq
  453. Sea Lane Biotechnologies
  454. SEEDS Capital
  455. Selecxine
  456. Sequoia Capital China
  457. Serum Institute of India
  458. Sevion Therapeutics
  459. Shanghai Junshi Biosciences
  460. Shenyang Sunshine Pharmaceuticals
  461. Shenzhen GTJA Investment Group
  462. Shenzhen Hepalink Pharmaceutical
  463. Shenzhen Innovation Capital Investment
  464. Shire
  465. Shilps Sciences
  466. Sichenzia Ross Ference
  467. Sichuan Kelun-Biotech Biopharmaceutical
  468. Siegfried Holding
  469. Silverton Partners
  470. Simcere Pharmaceutical
  471. Simon Fraser University
  472. Single Cell Technology
  473. Sino Biological
  474. Sinobioway
  475. SK Holdings
  476. Sofinnova Partners
  477. Sorrento Therapeutics
  478. SOTIO
  479. South Dakota Equity Partners
  480. Specifica
  481. Standford University
  482. State Development & Investment
  483. State of Wisconsin Investment Board (SWIB)
  484. Straterx
  485. Summit Partners
  486. Surface Oncology
  487. Surveyor Capital
  488. Sutro Biopharma
  489. Suzhou Oriza Holdings
  490. Syd Labs
  491. Symphogen
  492. Synbio Technologies
  493. Syngene
  494. TA Associates
  495. Takeda
  496. Talem Therapeutics
  497. Tanabe Research Laboratories
  498. Tasly Biopharmaceuticals
  499. Technical University of Denmark
  500. Telix Pharmaceuticals
  501. Temasek Holdings
  502. TeneoBio
  503. TESARO
  504. TetraGenetics
  505. Teva Pharmaceutical Industries
  506. TG Therapeutics
  507. The University of Texas MD Anderson Cancer Center
  508. The Wistar Institute
  509. Theraclone Sciences
  510. Theranyx
  511. Thermo Fisher Scientific
  512. Thiel Capital
  513. Third Point Ventures
  514. Third Venture Biopharma
  515. Tasgen Bio-Tech
  516. ThromboGenics
  517. Tizona Therapeutics
  518. Tmunity Therapeutics
  519. Torch Biosciences
  520. TRACON Pharmaceuticals
  521. Transcenta Holding
  522. Transgene
  523. TRIANNI
  524. Tri-Institutional Therapeutics Discovery Institute
  525. Tsinghua University
  526. Twist Bioscience
  527. UK Innovation & Science Seed Fund
  528. University College London
  529. University of Navarra
  530. University of Oxford
  531. University of Southampton
  532. University of Surrey
  533. University of Technology Sydney
  534. University of Texas
  535. U-Protein Express
  536. US Department of Defense
  537. Vaccinex
  538. Vall d'Hebron Institute of Oncology
  539. Valneva
  540. Velabs Therapeutics
  541. venBio
  542. Vertex Holdings 
  543. VI Ventures
  544. Vinnova
  545. Vir Biotechnology
  546. Visterra
  547. Vital Venture Capital
  548. Viva Biotech
  549. Voyager Therapeutics
  550. Washington University School of Medicine
  551. Watson Investments
  552. Wellington Management
  553. Wisconsin Alumni Research Foundation
  554. Woodford Investment Management
  555. Woodford Patient Capital Trust
  556. WuXi AppTec
  557. Wuxi Biologics
  558. XBiotech
  559. xCella Biosciences
  560. Xencor
  561. XOMA
  562. Yale Cancer Center
  563. Yinuoke
  564. YUMAB
  565. Yurogen Biosystems
  566. Zai Lab
  567. Zebra Biologics
  568. Zhejiang Teruisi Pharmaceutical
  569. Zheshang Venture Capital
  570. Zumutor Biologics
  571. Zurich Cantonal Bank
  572. Zydus Cadila
  573. Zymeworks

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experienceAccept

Copyright © Roots Analysis. All Rights Reserved.